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IRRADIATION INFLUENCES ENDOTHELIAL CELL FUNCTION IN VITRO
AND IN VIVO: A POSSIBLE ROLE FOR IP10
Cannella, L.; Laylor, R.; Marelli-Berg, F.; Dazzi, F. Department of
Immunology, Imperial College, London, United Kingdom.
The cytokine storm induced by the pre-transplant conditioning
regimen, plays a major role in the development of graft-versus-host
disease (GVHD) by enhancing antigen presentation and recruiting
donor T cells to the tissues. Some of the cytokines implicated in
GVHD also activate vascular endothelium and might inﬂuence
lymphocyte trafﬁcking. We hypothesised that in addition, endo-
thelial cells (EC) irradiation contributes to their activation thus
enhancing leukocyte trafﬁcking. T cell migration through irradi-
ated or non irradiated lung-derived endothelial cell (EC) mono-
layer was measured at various intervals. We observed that, inde-
pendently of the dose used, irradiation signiﬁcantly increased the
proportion of migrating T cells at each time point. This effect
could either be due to cytoskeletal rearrangements and/or to sol-
uble factors induced by irradiation. Irradiation induced in the EC
a dose-dependent re-organization of actin stress ﬁbres. In addition,
supernatants obtained from irradiated endothelium induced T cell
chemotaxis in vitro. The chemotactic effect was signiﬁcantly re-
duced (51 to 63% inhibition) by the addition of an antibody
neutralizing the chemokine IP10. The migration pattern of T cells
was also investigated in an in vivo model in which CFSE labelled
donor T cells were infused in irradiated (1000 cGy) or untreated
(control) syngeneic recipients. Although the proportion of injected
T cells in the lymphoid organs was much higher in the irradiated
than in control hosts, the overall pattern of migration was similar.
The distribution of donor inﬁltrating cells was homogeneously
diffuse in the control group whilst clustered in follicles in irradiated
mice. We conclude that irradiation inﬂuences the migration of
donor T cells possibly via an increased production of IP10 by EC.
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TWICE-DAILY INTRAVENOUS BOLUS TACROLIMUS INFUSION FOR
ACUTE GRAFT-VS-HOST DISEASE PROPHYLAXIS
Hayek, F.N.1; Al-Ghawi, H.1; Allen, J.1; Baize, T.1; Mudd, L.2;
Mehta, A.2; Soni, S.1; Cheerva, A.1; Herzig, G.P.1; Herzig, R.H.1 1.
University of Louisville, James Graham Brown Cancer Center, Louis-
ville, KY; 2. University of Louisville, Department of Pediatrics, Louis-
ville, KY; 3. University of Louisville, Department of Bioinformatics &
Biostatistics, Louisville, KY.
Background: Tacrolimus (FK) is usually given as a continuous
24-hour infusion for acute graft-vs-host disease (GVH) prophylaxis
in the setting of allogeneic hematopoietic stem cell transplantation
(HSCT). Often, this schedule becomes logistically difﬁcult and
requires dedicated line and monitoring. We report our experience
with the use of twice-daily intravenous (IV) bolus injection. Pa-
tients and Methods: Between 01/00–06/04, 59 patients (pts) with
hematologic indication for allogeneic HSCT received twice-daily
FK for GVH prophylaxis. Patients were given FK at initial dose of
0.015 mg/kg IV bolus over 3 hours on day T 1 then every 12
hours. First trough level was drawn before the seventh dose on day
T 2 and then twice weekly unless clinically indicated otherwise.
Doses were adjusted for a target level of 10 ng/ml (range 5–20
ng/ml). Patients were switched to oral form when were clinically
able to tolerate it. Results: Median age was 49 years (range 19–64
y). Donors were transplanted for hematologic disorder indications.
Donor compatibility status was as follows: matched-related 38
(64.4%), matched-unrelated 10 (17%), and mismatched-related 11
(18.6%). FK was used in 2 GVH prophylaxis protocols: with
methotrexate or in combination with mycophenolate mofetil and
daclizumab. Median ﬁrst trough level was 9 ng/ml (range 2.6–
22.5). Rate of grade I or II acute GVH was 16.9%. Only one pt
developed grade III (1.7%) and no pt had grade IV. Signiﬁcant
nephrotoxicity (peak creatinine level 2 baseline or 2 mg/dl)
occurred in 16 patients (27.1%). Five of these pts (31.25%) had at
least 1 FK trough level 20 ng/ml whereas 15 of 44 patients with
normal renal function (34.1%) had such elevated levels. Severe
nephrotoxicity requiring dialysis occurred in 4 pts and only 1 of
these had elevated FK level. One pt developed HUS/TTP and had
all FK trough levels 
20 ng/ml. There were no grade 3 or 4
seizures or tremors. Median discharge day was T 19 (range
12–34). Two pts relapsed, but were alive, by day 100. Day-100
relapse-free mortality was 18.6%. Conclusion: Results of twice-
daily bolus tacrolimus compare favorably to historical safety and
efﬁcacy data of continuous infusion of FK in allogeneic HSCT.
Bolus infusion was easy to administer and adjust and did not
correlate with increased risk of nephrotoxicity. These results
should be further investigated in a prospective clinical trial.
133
STEM CELL MOBILIZATION WITH NOVEL G-CSF ANALOGUES AUGMENT
NKT CELL RESTRICTED GRAFT-VERSUS-LEUKAEMIA EFFECTS
Morris, E.S.1,2; MacDonald, K.P.A.1; Rowe, V.1; Banovic, T.1; Kuns,
R.D.1; Olver, S.D.1; Kienzle, N.1; Porcelli, S.A.3; Pellicci, D.G.4;
Godfrey, D.I.4; Smyth, M.J.5; Hill, G.R.1,2 1. Queensland Institute of
Medical Research, Brisbane, Queensland, Australia; 2. Royal Brisbane
Hospital, Brisbane, Queensland, Australia; 3. Albert Einstein College of
Medicine, New York, NY; 4. University of Melbourne, Melbourne,
Victoria, Australia; 5. Peter MacCallum Cancer Centre, Melbourne,
Victoria, Australia.
We have studied the effect of stem cell mobilization with the potent
G-CSF and Flt-3 receptor agonist progenipoietin-1 (ProGP-1) on
graft-versus-leukaemia effects (GVL) in the B6 3 B6D2F1 murine
model of allogeneic stem cell transplantation (SCT). Donor pre-
treatment with ProGP-1 signiﬁcantly improved leukaemia free sur-
vival compared to G-CSF or control diluent pre-treatment (73%
versus 31% and 0% respectively; P
0.05) due to both reduced graft-
versus-host disease (GVHD) mortality (23% versus 55% and 100%
respectively; P
0.05) and prevention of leukaemic progression (4%
versus 30%, ProGP-1 versus G-CSF; P0.01). To dissect the mech-
anism responsible for the paradoxical enhancement of GVL we de-
veloped an in vivo cytotoxicity assay that reﬂects the killing of CD45.1
disparate donor versus CFSE labelled host splenocytes after SCT.
Anti-host cytotoxicity was signiﬁcantly enhanced when donors were
mobilised by ProGP-1 rather than G-CSF (cytotoxicity index 6.6 	
1.0 vs 3.1	 0.3, P0.01). We then utilized wild-type, perforin, FasL,
TNF or TRAIL deﬁcient donor grafts which were depleted of
CD4 and/or CD8 T cell subsets to study the molecular pathways
involved. The reduction in leukaemic progression in recipients of
ProGP-1 treated grafts was a consequence of a 2-fold increase in
anti-host cytotoxicity by donor CD8 T cells and was perforin-
restricted (P
0.01). ProGP-1 also prevented GVHD directed to
multiple minor histocompatibility antigens in the B63 Balb/Bmodel
despite enhancing anti-host cytotoxicity. The addition of Flt-3L to
G-CSF during stem cell mobilization or the addition of puriﬁed
CD11chi dendritic cells to G-CSF mobilized grafts failed to augment
donor anti-host cytotoxicity or further separate GVHD and GVL.
Conversely, stem cell mobilization with pegylated-G-CSF to prolong
G-CSF receptor stimulation prevented GVHD and reproduced the
augmentation of cytotoxicity seen in recipients of ProGP-1 mobilized
grafts. Mobilization with ProGP-1 signiﬁcantly increased splenic and
hepatic invariant NKT cell numbers and increased IFN- secretion
following in vitro stimulation with -GalCer analogues. Strikingly,
the augmentation of donor CD8 T cell cytotoxicity following mo-
bilization with ProGP-1 was lost whenNKTdeﬁcient (J18/) mice
were utilized as donors. Thus, enhanced G-CSF signalling by potent
G-CSF receptor agonists during stem cell mobilization augments
NKT cell dependent CD8 cytotoxicity following SCT and pro-
foundly separates GVHD and GVL.
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SUICIDE GENE THERAPY FOR HUMAN T CELL MEDIATED GRAFT VER-
SUS HOST DISEASE IN A MURINE XENOGRAFT MODEL
Nervi, B.1; Rettig, M.P.1; Ritchey, J.1; Walker, J.1; Bauer, G.1;
Herrbrich, P.E.1; Bonyhadi, M.L.2; Nolta, J.A.1; DiPersio, J.F.1 1.
Washington University School of Medicine, St. Louis, MO; 2. Xcyte
Therapies, Inc., Seattle, WA.
Graft-versus-host disease (GvHD) remains a major cause of mor-
bidity and mortality following allogeneic bone marrow transplan-
tation. We developed a novel chimeric suicide gene in which the
Poster Session I
45B B & M T
